The VIDIO study, led by Paul Gagne, Southern CT Vascular Center, Darien, USA, showed that intravenous ultrasound (IVUS) is more sensitive for assessing treatable iliofemoral vein stenosis compared with multiplanar venography and frequently leads to revised treatment plans and the potential for improved clinical outcome.
Twelve-month results from the SENTRY trial evaluating the Sentry bioconvertible inferior vena cava (IVC) filter (Novate) have shown a 0% rate of symptomatic pulmonary embolism, no instances of device failure and a 96% rate of bioconversion. Presenting that data at the Vascular Interventional Advances 2017 conference (VIVA; 11–14 September, Las Vegas, USA), principal investigator Michael Dake (Stanford, USA) said that the data represent “an important paradigm shift in the prevention of pulmonary embolism”.
Spectranetics has recalled the Bridge occlusion catheter “due to the possibility of a blocked guidewire lumen in some device units”. Using affected catheters could lead to the incorrect positioning of the device and subsequent uncontrolled haemorrhage.
A study has shown modified human factor X to be a safe and effective reversal agent for prevention and treatment of bleeding in patients taking factor Xa oral anticoagulants. This new therapeutic factor X was inspired by a snake venom protein.
Data from the LAMA (Laser ablation versus mechanochemical ablation) trial indicate that mechanochemical ablation (MOCA) is significantly less painful than endovenous laser ablation (EVLA) during treatment of superficial venous incompetence, though there is no difference in pain between the two treatments when the pain of phlebectomy is taken into account. Both techniques significantly improved clinical severity and quality of life in this trial.
The first comprehensive European advice on deep vein thrombosis was recently published in the European Heart Journal. The recommendations were produced by the European Society of Cardiology (ESC) Working Group on Aorta and Peripheral Vascular Diseases and Working Group on Pulmonary Circulation and Right Ventricular Function.
Inari Medical has announced that it has completed enrolment of its investigational device exemption (IDE) study. The FlowTriever Pulmonary Embolectomy Clinical Study (FLARE) study is designed to evaluate the safety and effectiveness of the FlowTriever Retrieval/Aspiration System for the treatment of pulmonary embolism.
Endovascular treatment of iliocaval and infrainguinal post-thrombotic venous obstruction results do not appear to be adversely affected by extension of the iliac vein stents into the femoral venous system, according to a US report in the Journal of Vascular Surgery: Venous and Lymphatic Diseases.
While comparative study data for venous stents are still lacking, results of a number of ongoing and planned venous stent trials will increase the options currently available to physicians and provide useful comparative data, explained Stephen Black (London, UK), giving a venous stent trial update at the 2017 THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA).
Inferior vena cava (IVC) filters have been a highly controversial topic in the field of venous medicine due to the high rates of complications associated with their use, which eventually prompted a 2010 US Food and Drug Administration (FDA) advisory and declining use. This year, an article by the editor of JAMA Internal Medicine—Rita F Redberg (University of California, San Francisco, USA)—suggested, “There should be a moratorium on [IVC filter] use unless or until there are data showing efficacy greater than risk.” At the 2017 THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA) Venous News spoke to John Kaufman (Dotter Interventional Institute, Portland, USA) to hear his opinion on the moratorium call, and how IVC filter use can be optimised for the safest and the best outcomes.
The US Centers for Medicare and Medicaid Services (CMS) has posted the 2018 Medicare Physician Fee Schedule (CMS-1678-F) and Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems (CMS-1678-FC). As part of the final rulings, healthcare providers will now be able to bill for VenaSeal utilising the new CPT codes 36482 and 36483. These new codes will take effect on 1 January, 2018.
Cardiff Metropolitan University has successfully secured funding to support an interdisciplinary collaboration arising from the Welsh Crucible programme that looks at the design and development of an innovative sterilising device for venous access ports (VAPs).
Cardiff Metropolitan University has announced it has secured a grant to “support an interdisciplinary collaboration of an innovative sterilising device for venous access ports (VAPs).”
At THE VEINS at VIVA meeting (10–11 September 2017, Las Vegas, USA), James Froehlich, University of Michigan, Ann Arbor, USA, reviewed guidelines on the management of superficial venous thrombosis (SVT) and emphasised the importance of performing duplex ultrasound in the examination, assessing clot location and extent, considering the risk factors for recurrence and development of deep vein thrombosis (DVT), and discussing with the patient their options on the use of anticoagulants.
At the THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA), Esther Kim (Vanderbilt University Medical Center, Nashville, USA) gave a presentation on venous thrombosis in unusual locations, noting that such thromboses tend to occur in younger patients and those with malignancy, and that thrombophilia has a role in most cases and testing for it may be considered.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos